Clinical trialPhase 2 / Phase 3Unknown
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma
- Outcome
- Outcome unknown
- Phase
- Phase 2 / Phase 3
- Status
- Unknown
- Study type
- Interventional
- Start
- December 2009
- Enrollment
- 64 participants
- Sites
- 1
- Primary outcomes
- To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 29 January 2014
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. The purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only venous involvement. Group II patients have arterial involvement and may also have venous involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer.